DIRS.INFO The most relevant business & tech news

☆ Generative AI will be designing new drugs all on its own in the near future
▼ + stars: | 2024-05-05 | by ( Trevor Laurence Jockims | ) www.cnbc.com time to read: +12 min

An analogy for understanding the development of AI drugs can be found in the mechanisms of ChatGPT. As a result, it's a drug discovery process that has a 90% failure rate. Some of the noted flaws of generative AI, its propensity to "hallucinate" for example, could prove to be powerful in drug discovery. AI is learning to distinguish drugs from non-drugs, and to create new drugs, in the same way that ChatGPT can create sentences, Ellington said. Now, AI models are helping narrow down the possibilities, so scientists more quickly know the optimal modifications to try.

Persons: ChatGPT, Kimberly Powell, Google's, —, AlphaFold, Powell, Rau, Lilly, Eli Lilly, Diogo Rau, It's, Amgen, Andy Ellington, Ellington, Daniel Diaz, Diaz, We've Organizations: Nvidia, CNBC Technology, Summit, University of Texas, Austin, NVIDIA, biosciences, UT's Institute, Foundations of Machine, Cadence Locations: Nature

☆ Earnings will drive the market next week — what we expect from 2 portfolio stocks
▼ + stars: | 2024-05-04 | by ( Zev Fima | ) www.cnbc.com time to read: +10 min

With the Fed, Apple earnings and the jobs report passing with flying colors this week, the runway to more gains looks a lot less cluttered. This past week was chock full of Club earnings: 12 portfolio companies, including Apple , delivered results. Analysts expect Wynn's earnings per share of $1.27 versus 29 cents a year ago when China was not fully back from Covid. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Jerome Powell, we're, Jim Cramer, Jim, Apple, Eli Lilly, Estee Lauder, Stanley Black, Decker, Bausch, FactSet, It's, Bob Iger, Iger, Nelson Peltz, We're, Krystal, Berkshire Hathaway, Tyson, Jones Lang, Walt, Ferrari N.V, WK Kellogg, Wynn, Vishay, CRON, MARA, RICK, Ginkgo, Jim Cramer's, David Paul Morris Organizations: Federal Reserve, Apple, GE Healthcare, DuPont, Linde, Bausch Health, Coterra Energy, Club, Disney, Wynn Resorts, CNBC, Revenue, Vegas Sands, Cotai, Boston, Airlines, Krystal Biotech, Alpha Metallurgical Resources, Axsome Therapeutics, Tyson Foods, TSN, Bowlero Corp, CNA Financial Corp, CNA, Jones Lang LaSalle Incorporated, Technologies, Realty Income Corp, Lab, Teradata Corp, Technology, FMC Corporation, FMC, Paymentus Holdings, Shockwave, Vertex Pharmaceuticals, Goodyear Tire & Rubber Company, Simon Property Group, Sterling Construction Company, Apple Hospitality, Boise Cascade Corporation, BellRing Brands, Coty, COTY, Fidelity National Information Services Inc, Vornado Realty, Walt Disney Co, Holdings, Madrigal Pharmaceuticals, Nikola Corporation, BP, Rockwell Automation, MarketAxess Holdings, Jumia Technologies, GEO Group, Builders FirstSource Inc, Duke Energy Corp, WYNN, Rivian Automotive, Arista Networks, Occidental Petroleum Corp, Astera Labs, Bros, Flywire Corporation, B2Gold Corp, Kinross Gold Corp, Virgin Galactic Holdings, iRobot Corp, Electronic Arts Inc, McKesson Corp, ACM Research, Avadel Pharmaceuticals, Toyota Motor Corp, Emerson Electric Co, Perion, Editas, Brink's Company, Sinclair Corporation, New Fortress Energy, Starwood Property Trust, Animal Health, ELAN, Farms, IM Cannabis Corp, Fox Corporation, Formula One, Icahn Enterprises, Teva Pharmaceutical Industries, Arm Holdings plc, ARM, AMC Entertainment Holdings, Trade, AppLovin Corporation, Sciences Corp, SolarEdge Technologies, Roblox Corporation, GigaCloud Technology Inc, Warner Bros ., Properties Trust, Growers, Constellation Energy Group, Cronos, Fiverr, Solar Inc, EPAM Systems, Cedar Fair Entertainment, Digital Holdings, RCI Hospitality Holdings, Akamai Technologies, Semiconductor, Insulet Corp, NuScale Power Corporation, Ginkgo Bioworks Holdings, Bloom Energy Corporation, Construction, AMC Networks, CRH Public Ltd . Company, Jim Cramer's Charitable, Allen, Co . Media, Technology Conference, Bloomberg, Getty Locations: China, Eaton, Amazon, Covid, Macao, Vegas, Sun Valley , Idaho

☆ Citi names 3 biotech stocks to play a growing $2.9 billion opportunity — giving one about 50% upside
▼ + stars: | 2024-05-01 | by ( Weizhen Tan | ) www.cnbc.com time to read: +2 min

The outlook is starting to look bright for biotech stocks, according to some. With markets now expecting the first rate cut to be in September rather than June or July, as previously thought, biotech stocks could start to do well. Biotech encompasses many different areas, but Citi has identified one with a $2.9 billion market — which it says is set for even more growth. It gave CSL a price target of $305, or nearly 11% potential upside. It gave Intellia a price target of $31, or 49% potential upside.

Persons: Morgan Stanley, Garadacimab, Ionis, Citi Organizations: Biotech, Citi, Ionis Pharmaceuticals, Intellia Therapeutics, CSL, Intellia

☆ Here are Tuesday's biggest analyst calls: Nvidia, Tesla, Apple, Live Nation, Boeing, Coinbase, Amazon & more
▼ + stars: | 2024-04-30 | by ( Michael Bloom | ) www.cnbc.com time to read: +5 min

Bank of America reiterates Tesla as buy Bank of America said it's standing by its buy rating on the electric-vehicle maker. "We maintain our Buy rating and raise our PT from $1100 to $1,150." "We are initiating coverage of Live Nation with a Buy rating and $120 price target." "We are initiating coverage on EE with an Overweight rating." "We are initiating coverage of Integral Ad Science with a Buy rating and a $15 price target."

Persons: Tesla, TSLA, Morgan Stanley, Oppenheimer, Raymond James, Mizuho, Airbnb, Coinbase, Needham, Stephens, Jefferies, Ralph Lauren, Chegg Organizations: Argus, Boeing, " Bank of America, Bank of America, UBS, Nvidia, Dyne, JPMorgan, Catalyst Watch, Apple, Mizuho, Citi, BTC, Ethereum, Paramount, CBS, Deutsche Bank, Deutsche, Excelerate Energy, Stephens, Barclays, UMB, Corp, Contineum Locations: Base, Kansas City

☆ Mental-health professionals explore AI-powered digital therapeutics to treat patients and improve care
▼ + stars: | 2024-04-29 | by ( Christine Macintyre | ) www.businessinsider.com time to read: +8 min

The fusion of human ingenuity and machine intelligence is offering an innovative approach to personalized mental-health care. They can also use AI to assess the quality of their services and find ways to improve as providers of mental-health care. As technology becomes more involved in mental-health care, ensuring data security, confidentiality, and equitable access to services must be top priorities. How an AI platform is helping mental-health-care providers improve their servicesThe AI platform Lyssn is another tech-driven tool for mental-health services. Lyssn aims to hold providers accountable for improved care, especially because "the quality of mental-health care is highly variable," Imel said.

Persons: —, Christopher Romig, Stella, Shaheen Lakhan, Daniel Rimm, Haig Goenjian, Zac Imel, Michael Tanana, Imel, Darin Carver, Carver, It's Organizations: Service, Therapeutics, Click Therapeutics, Food and Drug Administration, Weber Human Services Locations: Tanana

☆ Corporate earnings solid so far, despite threats from a slowing economy and sticky inflation
▼ + stars: | 2024-04-29 | by ( Bob Pisani | ) www.cnbc.com time to read: +6 min

Valuations coming down So if earnings are up, why is the S & P off its highs? Today, a month later, 2024 earnings estimates are essentially the same but the multiple has declined to 20.8. The S & P 500 hit a low of 4,117 on Oct. 27 and only recovered when rates came down in early November. There are some big drags on earnings Some companies are seeing large declines in earnings estimates that are weighing on their sectors. When including this one-time item, the S & P 500 earnings growth rate for the first quarter declines to 5.6%, from 8.7%, LSEG has noted.

Persons: Goldman Sachs, JPMorgan Chase, Morgan Stanley, Christopher Suh, Stephen Squeri, Hess, Nick Raich, LSEG, Hal Lawton, Brian Niccol, CNBC's Kate Rogers, Horton, Paul Romanowski, Kimberly, Clark, Michael Hsu Organizations: Companies, Netflix, JPMorgan, GE Aerospace, Caterpillar, Microsoft, Merck, Ford, Waste Management, Royal, Consumer, American Express, Energy, Marathon Petroleum, Apache, Valero Energy, Oil, Occidental Petroleum, Devon Energy, ConocoPhillips, Exxon Mobil, Scout, Bristol Myers Squibb, Karuna Therapeutics, Boeing, Nvidia, Meta, AMD Locations: financials, industrials, Royal Caribbean, North America

☆ Here are Monday's biggest analyst calls: Apple, Nvidia, AT&T, Tesla, Shopify, Super Micro Computer and more
▼ + stars: | 2024-04-29 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Evercore ISI reiterates Tesla as in line Evercore ISI lowered its price target on Tesla to $145 per share from $155. Barclays upgrades AT & T to overweight from equal weight Barclays sees "growth quality" for the telecommunications and wireless provider. Barclays downgrades Lululemon to equal weight from overweight Barclays downgraded the maker of athleisure wear due to rising competition. "We initiate coverage of Dave Inc. with a Market Outperform rating and $70 price target representing ~65% upside from the current price." "We are upgrading GWW from EW to OW, while raising our price target from $1,000 to $1,250."

Persons: Evercore, Tesla, Jefferies, LUV, Lululemon, LULU, Dave, Oppenheimer, Instacart, Bernstein, Goldman Sachs, William Blair, Eastman, Morgan Stanley, Berenberg, Melius, Price, Stephens, Grainger Organizations: Airlines, Jefferies, Southwest Airlines, Dynamics, Barclays, Dave Inc, JPMorgan, CART, Apple, Eastman Chemical, Arista Networks, Nvidia, Data, Citi Locations: Americas, China, Tulsa , Oklahoma, Kingsport , Tennessee

☆ ‘This is a unique time’: ARK Invest’s chief futurist tackles tech innovation from AI to robotics
▼ + stars: | 2024-04-27 | by ( Meredith Mutter | ) www.cnbc.com time to read: +1 min

ARK Invest's chief futurist lists five groups that should give tech investors an edge. "We believe that this is a unique time in technological economic history," he told CNBC's "ETF Edge" this week. Winton collaborates with ARK Invest CEO Cathie Wood to maintain the ARK Venture Fund (ARKVX), which allows investors to buy into the private technology space. "That's a real challenge a lot of public market investors don't have that long-term view," Winton added. The ARK Venture Fund is down more than 7% so far this year.

Persons: ARK, Brett Winton, CNBC's, Winton, Cathie Wood Organizations: ARK, ARK Venture, Epic, Therapeutics

☆ FDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder
▼ + stars: | 2024-04-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

The Food and Drug Administration on Friday approved Pfizer 's treatment for a rare genetic bleeding disorder, making it the company's first-ever gene therapy to win clearance in the U.S. The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B who meet certain requirements. Without that protein, called factor IX, patients with hemophilia B bruise easily and bleed more frequently and for longer periods of time. The gene therapy will compete with Australia-based CSL Behring's Hemgenix, a similar treatment that won FDA approval for hemophilia B in 2022. The company is also developing a gene therapy for Duchenne muscular dystrophy, a genetic disorder that causes muscles to weaken gradually.

Persons: IX, hemophilia, Adam Cuker, Cuker Organizations: Drug Administration, Pfizer, U.S, Penn's, Spark Therapeutics, hemophilia Locations: U.S, Australia

☆ Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
▼ + stars: | 2024-04-25 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Merck on Thursday reported first-quarter revenue and adjusted earnings that topped expectations as it posted strong sales of its blockbuster cancer drug Keytruda and vaccine products. The pharmaceutical giant also raised and narrowed its full-year revenue and adjusted earnings forecasts. Merck now expects 2024 sales to come in between $63.1 billion and $64.3 billion, up from previous guidance of $62.7 to $64.2 billion. That outlook includes a one-time charge of roughly 26 cents per share related to Merck's acquisition of Harpoon Therapeutics in January. Merck raked in $15.78 billion in revenue for the quarter, up 9% from the same period a year ago.

Persons: Merck Organizations: Merck, Harpoon Therapeutics, LSEG Locations: Rahway , New Jersey, U.S

☆ Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss
▼ + stars: | 2024-04-25 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, US, on Wednesday, Dec. 27, 2023. Bristol Myers Squibb on Thursday reported first-quarter revenue that topped expectations as its blockbuster blood thinner Eliquis and several new drugs posted sales growth. Two-thirds of savings are associated with drug research and development, Bristol Myers Squibb executives said during an earnings call on Thursday. Those deals come as Bristol Myers faces pressure to launch new drugs and offset the potential loss of revenue from top-selling treatments. Shares of Bristol Myers fell more than 1% in premarket trading Tuesday.

Persons: Bristol Myers, Samit Hirawat, Chris Boerner, Boerner, Revlimid Organizations: Bristol Myers Squibb, Bristol Myers, Karuna Therapeutics, SystImmune, Bristol, LSEG Locations: Cambridge, Cambridge , Massachusetts, Here's

☆ Grandmother Becomes Second Patient to Receive Kidney From Gene-Edited Pig
▼ + stars: | 2024-04-24 | by ( Roni Caryn Rabin | ) www.nytimes.com time to read: 1 min

A severely ill 54-year-old woman earlier this month became the second person to receive a kidney transplanted from a genetically modified pig, surgeons at NYU Langone Health in New York announced on Wednesday. The patient, who had both heart failure and kidney failure, was given the organ on April 12, just eight days after receiving a mechanical heart pump. Surgical teams at NYU Langone carried out the two procedures over the course of nine days. The kidney came from a genetically engineered pig provided by United Therapeutics Corporation, a biotech company. The pig carried a gene for producing a sugar called alpha-gal that had been “knocked out,” or blocked.

Persons: NYU Langone, Lisa Pisano, “ Organizations: NYU Langone Health, NYU, United Therapeutics Corporation Locations: New York, New Jersey

☆ Here are Monday's biggest analyst calls: Apple, Nvidia, Tesla, Meta, Amazon, Microsoft, Spotify, Ferrari & more
▼ + stars: | 2024-04-22 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Morgan Stanley reiterates Apple as overweight Morgan Stanley lowered its price target on the stock to $210 per share from $220 but says it's sticking with Apple. Bank of America reiterates Amazon as buy Bank of America said it's bullish heading into Amazon earnings next week. Bank of America reiterates Tesla as neutral Bank of America said it's sticking with its neutral rating on Tesla shares. Morgan Stanley upgrades Alcoa to equal weight from underweight Morgan Stanley said it sees a more balanced risk/reward for shares of Alcoa. Bank of America reiterates Apple as buy Bank of America says Apple is a top pick at the firm.

Persons: Goldman Sachs, Goldman, Morgan Stanley, it's, Piper Sandler, Piper, Apple, Q, Q revs, Papa, Stifel, Papa John's, Jefferies, Mizuho, JPMorgan, Raymond James downgrades, Raymond James, TD Cowen, BRBR, BMO downgrades, Tesla, Oppenheimer Organizations: Nvidia, NVIDIA, RBC, Apple, Microsoft, Meta, Bank of America, JPMorgan, Cisco, Deutsche Bank, Realty Trust, Deutsche, Brands, BMO, of America, Alcoa, Kymera Therapeutics, " Bank of America Locations: Singapore, Asia, Brazil

☆ 6 portfolio stock earnings and the Fed's favorite inflation gauge dominate the week ahead
▼ + stars: | 2024-04-20 | by ( Zev Fima | ) www.cnbc.com time to read: +11 min

The Nasdaq sank 2% on Friday as Netflix dropped nearly 11% post-earnings and Club stock Nvidia fell 10%, entering bear market territory but still up more than 50% in 2024. Following a much stronger-than-expected March retail sales report last month, fresh economic data and six Club stock earnings will take center stage in the week ahead. While lower rates may help stock multiples, that is not a sustainable path to higher equity prices over time. Earnings : The latest quarterly reporting season is starting to ramp into high gear with six Club names set to report next week. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Dow, Jerome Powell, Jim Cramer, Mark, Meta, Bing, Ford, Vimal, Lockheed Martin, Clark, Philip Morris, Sherwin, Williams, Baker Hughes, Lam, Northrop, Dr Pepper, CARR, Edwards Lifesciences, Jim Cramer's, Jim, Michael M Organizations: Nasdaq, Netflix, Nvidia, Dow Jones, Federal, Fed, Hamas, Gross, Google, Reality Labs, General Motors, Honeywell, Microsoft, Verizon Communications, Albertsons Companies, SAP, Cadence Design Systems, United Parcel Service, General Electric, GE, PepsiCo, Lockheed, Spotify Technology, RTX Corporation, JetBlue Airways, Halliburton, HAL, Philip Morris International, Quest Diagnostics, Texas Instruments, Seagate Technology, Mattel, Veralto Corporation, Boeing, General Dynamics, Boston, Hilton, Fisher, Otis Worldwide, IBM, Grill, Viking Therapeutics, Lam Research, Whirlpool, WM, Honeywell International, Royal Caribbean Cruises, American Airlines, Altria, Newmont, Caterpillar, Southwest Airlines, Myers Squibb, AstraZeneca, Mobileye, Northrop Grumman, CNBC, Comcast, Merck, Dow Inc, Carrier Global, Union Pacific, Intel, Western, Mobile, L3Harris Technologies, Exxon Mobil, Chevron, Colgate, Palmolive, HCA Healthcare, Charter Communications, Newell Brands, Jim Cramer's Charitable, Traders, New York Stock Exchange, Santiago, Getty Locations: Israel, Iran, Ukraine, destocking, China, Cleveland, Freeport, McMoRan, Kimberly, Masco, Bristol, New York City

☆ WHO chief scientist calls for increased monitoring and preparation for highly pathogenic bird flu
▼ + stars: | 2024-04-19 | by ( Brenda Goodman | ) edition.cnn.com time to read: +4 min

CNN —The bird flu spreading through cattle in the United States is an “enormous concern” the chief scientist of the World Health Organization said Thursday as he called for more tracking and preparation for the virus. So far, there is no evidence that the highly pathogenic H5N1 flu virus can spread from person to person. Though H5N1 doesn’t spread from person to person, humans can catch it when they’re exposed to infected animals. They are only the second documented case of human H5N1 in the United States. The US Centers for Disease Control and Prevention says that while the current risk to public health from H5N1 is low, it is monitoring the situation carefully.

Persons: Dr, Jeremy Farrar, “, Richard Webby, ”, hasn’t, Sanjay Gupta Organizations: CNN, World Health Organization, WHO, Research, Get CNN, CNN Health, US Department of Agriculture’s, Plant Health, Services, US Centers for Disease Control, CDC Locations: United States, British, Geneva, Texas, Colorado, St, — Texas, New Mexico , Kansas, South Dakota , Idaho , Michigan , Ohio, North Carolina

☆ IPO market continues to open up, market downdraft be damned, but higher rates loom
▼ + stars: | 2024-04-18 | by ( Bob Pisani | ) www.cnbc.com time to read: +3 min

For proof that the market for initial public offerings continues to open up despite the downdraft in the market, just look at this week. This spring reopening, however, is threatened by the specter of higher interest rates. Why higher interest rates hurt IPOs The major headwind: higher for longer interest rates. technology) are more sensitive to a change in interest rates, because their cash flow projections are further out. Still, most admit higher rates make it more difficult to get investors excited about IPOs.

Persons: Ibotta, Rubrik, Matt Kennedy, IPOs, That's, Kennedy, Santosh Rao Organizations: Centuri Holdings, Southwest Gas Holdings, UL Solutions, Group, Renaissance Capital, Loar Holdings, Manhattan Venture Partners

☆ Counterfeit Botox has been found in several states. Here’s what consumers should know.
▼ + stars: | 2024-04-16 | by ( Jacqueline Howard | ) edition.cnn.com time to read: +11 min

CNN —The US Food and Drug Administration is warning that dangerous counterfeit versions of Botox have been identified in multiple states, putting the safety of consumers at risk. The incidents of counterfeit Botox being administered to consumers appear to be connected to products that have been purchased from unlicensed sources and then administered by either unlicensed or licensed providers. The counterfeit Botox products may be identified by the lot number C3709C3 found on the outer carton and vial, the FDA said. Counterfeit botox has been found in several states. Most often, when counterfeit Botox is sold, “the injector knows they’re purchasing something counterfeit,” Sung said.

Persons: Washington –, Botox, Lavanya Krishnan, Arya Derm, ” Krishnan, Krishnan, Allergan, ”, “, Jimmy Sung, you’re, can’t, ” Sung, Michael Cameron, Cameron, ” Cameron, Sung, “ I’m, I’ve, Steven Williams, ” Williams, Dr, Sanjay Gupta, Cynthia Elliott, ” Elliott Organizations: CNN, Food and Drug Administration, FDA, US Centers for Disease Control, CDC, American Board of Cosmetic, Revance Therapeutics, Merz Aesthetics, Tribeca Aesthetics, Cameron Dermatology, Mount Sinai Health, American Society of Plastic Surgeons, “, CNN Health Locations: – Colorado, Florida , Illinois , Kentucky , Nebraska , New Jersey , New York , Tennessee, San Francisco, United States, New York City, New York, Florida

☆ Stocks making the biggest premarket moves: Nike, CarMax, Robinhood, Alpine Immune Sciences and more
▼ + stars: | 2024-04-11 | by ( Michelle Fox | ) www.cnbc.com time to read: +2 min

Nike — Shares added 2% following an upgrade at Bank of America to buy from neutral. Alpine Immune Sciences — Shares of Alpine Immune Sciences soared nearly 37% after Vertex Pharmaceuticals said it will buy the company for about $4.9 billion in cash. The deal values Alpine stock at $65, about 67% above its close on Tuesday, the day before Bloomberg reported Alpine was considering its options. Vera Therapeutics — The stock jumped more than 10% following the announcement of the Vertex/Alpine deal. Atlassian — Shares jumped 4% after being upgraded at Barclays to overweight from equal weight.

Persons: Robinhood, Vera Therapeutics, Berenberg, DoorDash, Alex Harring, Sarah Min Organizations: LSEG, Revenue, Nike —, Bank of America, Citi, Constellation, Modelo, Constellation Brands, Immune Sciences, Vertex Pharmaceuticals, Bloomberg, Barclays, CNBC Locations: Vera, Albemarle

☆ Biotech stocks are ready to break out. They just need one more thing
▼ + stars: | 2024-04-10 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +5 min

While debate rages on about when the Federal Reserve might start cutting interest rates, biotech industry analysts are making the case that the argument for stocks in the sector is growing. Last week, Morgan Stanley analysts noted that it is the months leading up to an initial rate cut when biotech stocks outperform. Morgan Stanley also believes the case for biotech stocks is further reinforced by the financing environment and the outlook for mergers and acquisitions as well as upcoming innovation. The case for innovation Morgan Stanley also favors owning biotech stocks that have a strong drug platform even if the key catalyst of clinical trial data and FDA approvals are farther out. Rhythm ranks among the stocks rated overweight that Morgan Stanley favors in this category.

Persons: Morgan Stanley, Needham, Joseph Stringer, dealmaking, Stringer, erosive, it's, Phathom, GERD, LSEG, Merck, — CNBC's Michael Bloom Organizations: Federal Reserve, Nasdaq, Oncology, Immunology, Phathom Pharmaceutical, Pharmaceuticals, Phathom Pharmaceuticals, LSEG, Drug, Bristol Myers Squibb, Pfizer, Intellia Therapeutics, Rocket Pharmaceuticals Locations: New Jersey

☆ Record levels of funding propel Denver-Boulder to the top of the life sciences market
▼ + stars: | 2024-04-08 | by ( Chris Dilella | ) www.cnbc.com time to read: +7 min

The Denver-Boulder region is rapidly emerging as a major hub for the life sciences industry, attracting companies that develop cutting-edge medical treatments and technologies. Life sciences research aims to understand living things, from cells to our planet, to improve health, food and the environment. Founded in 2003, the Bioscience Association supports the growth of life sciences, with a focus on access to capital, education, networking and more. A recent CBRE report found Denver-Boulder to be the top U.S. life sciences real estate market, fueled by record investment from venture capitalists and the National Institutes of Health. Entrepreneurial successThe recent surge in venture capital flowing into Denver-Boulder builds on the area's proven track record of success over the past several decades.

Persons: Tim Schoen, BioMed, Schoen, Elyse Blazevich, Kevin Koch, Koch, Edgewise, We've, Dan LaBarbera, LaBarbera, Dr Organizations: BioMed, CNBC, Blackstone, Flatiron, Enveda Biosciences, Denver, Boulder, Colorado Bioscience Association, Bioscience Association, National Institutes of Health, U.S, Pfizer, Therapeutics, University of Colorado, Edgewise Therapeutics, Research, University of Colorado's Anschutz Medical, Center, Drug, Center for Drug, for Drug, Anschutz Medical Locations: CNBC's, Denver, Boulder, Diego, Boulder , Colorado, San Diego, San Francisco, Seattle, Boston, Cambridge, Massachusetts, Aurora, Rocky, Colorado, Boulder ., Denver's

☆ There’s still no standard test to detect pancreatic cancer early. Scientists are working to change that
▼ + stars: | 2024-04-08 | by ( Jacqueline Howard | ) edition.cnn.com time to read: +11 min

But there is no standard test to detect early cases of pancreatic cancer, before cancer cells have spread and when surgery is more likely to be helpful. But many studies investigating the potential of liquid biopsy tests for the early detection of pancreatic cancer are still in the early phases. The researchers found that their liquid biopsy approach detected 93% of pancreatic cancers among the US volunteers in their study, 91% of pancreatic cancers in the South Korean cohort and 88% of pancreatic cancers in the Chinese cohort. But there is no blood test that can detect early pancreatic cancer. “Smoking is the most important avoidable risk factor for pancreatic cancer,” according to the American Cancer Society.

Persons: ”, Brian Wolpin, ” Wolpin, “ There’s, Ajay Goel, ” Goel, “, Goel, Al Neugut, Columbia University’s Herbert, Dr, Sanjay Gupta, ” Neugut, “ It’s, It’s, Wolpin Organizations: CNN, Dana, Farber Cancer Institute, US Preventive Services Task Force, American Association for Cancer Research, Hope Comprehensive Cancer Center, Molecular Diagnostics, Therapeutics, Surgeons, University of Pennsylvania, UC San Diego, Columbia, Columbia University’s Herbert Irving Comprehensive Cancer Center, Columbia University Mailman School of Public Health, CNN Health, American Cancer Society Locations: United States, City, Japan, South Korea, China, City of Hope, Hope

☆ Loads of analysts just hiked price targets for these 6 stocks — giving one 82% upside
▼ + stars: | 2024-04-05 | by ( Ganesh Rao | ) www.cnbc.com time to read: +3 min

Analysts have become more bullish on six stocks from around the world this week, raising their price targets. The price target changes come ahead of the next earnings season covering the first quarter of this year. CNBC Pro screened for global stocks that have received price target upgrades from five or more analysts in the past seven days and have a potential upside of over 25%. MacroGenics Investment banks raised their price target for the biopharmaceutical firm MacroGenics this week, giving the stock upside potential of 83% over the next 12 months. Tuerkcan — one of the most cautious analysts on the stock — has a price target of $22, pointing to upside of 22% for the stock.

Persons: MacroGenics —, Silvan Tuerkcan, Peter Heckmann, DA Davidson, Jared Issacman's, Dan Dolev Organizations: Formula One, Hyundai Motor, CNBC Pro, Leerlink Partners, FactSet, Investment, DA, Visa, MasterCard, U.S, Mizuho Securities, Mar Locations: Korean, Rockville , Maryland, MacroGenics, York

☆ British billionaire Joe Lewis fined $5 million by U.S. judge for insider trading
▼ + stars: | 2024-04-04 | by ( ) www.cnbc.com time to read: +3 min

British billionaire and former owner of the Tottenham Hotspur Football Club Joe Lewis arrives at federal court for his sentencing in an insider trading case on April 4, 2024, in New York City. U.S. District Judge Jessica Clarke in Manhattan sentenced Lewis, who pleaded guilty in January to one count of conspiracy and two counts of securities fraud. Lewis in January entered a plea deal with prosecutors agreeing to a $50 million fine of his Bahamas company, Broad Bay. Under the agreement, Lewis' fine will be included in the total. Lewis has since remained in the country, posting $300 million bail secured by his yacht and a private aircraft.

Persons: Tottenham Hotspur Football Club Joe Lewis, Lewis, Joe Lewis, Jessica Clarke, Mr, Mark Herr, Prosecutors, Boxer Capital, Patrick O'Connor, Bryan Waugh Organizations: Tottenham Hotspur Football Club, US, Office, Southern, of New York, Tavistock Group, Aviva, London's Tottenham Hotspur, Boxer, Forbes, Prosecutors, Mirati Therapeutics, Boxer Capital, Tango Therapeutics Locations: New York City, U.S, Manhattan, London's, Bahamas, Broad Bay, London, New York

☆ The CEO of a weight-loss ETF that's crushing the S&P 500 since launching in November shares 4 stocks he sees with over 100% upside in the next 12 months
▼ + stars: | 2024-04-04 | by ( William Edwards | ) www.businessinsider.com time to read: +5 min

Weight-loss drugs like Ozempic, Wegovy, and Mounjaro are all the rage, and investors are noticing. Since launching in November, the Tema Obesity and Cardiometabolic ETF (HRTS) is up 24%, crushing the S&P 500's 14.8% returns over the same period. Pot and his colleagues at Tema are bullish on the weight-loss drug stocks due to the wave of demand they see coming. Novo Nordisk estimates that only 2% of obesity cases are being treated by weight-loss drugs, Pot said. 4 weight-loss drug stocks to watchPot listed two larger stocks and two smaller ones in the space.

Persons: Maurits Pot, Janus Henderson, Pot, Goldman Sachs, Geoff Meacham, Charles Barkley, Elon Musk, Whoopi Goldberg, Eli Lilly, Lilly Organizations: VanEck Pharmaceutical, Business, World Health Organization, Novo Nordisk, Bank of America, Bank, Nordisk, FDA, Amazon, Therapeutics, Zealand Pharma Locations: Tema, GLP, Danish, it's

Hedge fund managers gathered Wednesday at the 2024 Sohn Investment Conference in New York to share their best investment ideas. It kicked off with "Next Wave Sohn," a session that features ideas from rising stars within the hedge fund industry. Endocrinology is an $8 billion market, but the cumulative market size, including the company's future therapy targets, is upward of $200 billion, which includes estimates for future obesity drugs, the investor said. It has CA$75 billion market cap with an "unbelievable record of success," according to the investor. The short seller noted that the company has a $5 billion market cap with about $4.8 billion of debt.

Persons: Sohn, Eric Wolff, Wolff, Michelle Ross, Cushing, Ross, Eli Lilly, Crinetics, XBI, Nikhil Daftary, Alimentation, Daftary, Chris Drose, Nate Koppikar, Fahmi Quadir Organizations: Investment, Gumshoe Capital Management Investment, Pason Systems Energy, Pason Systems, Gumshoe Capital Management, StemPoint, Pharmaceuticals, Crinetics Pharmaceuticals, StemPoint Capital, Endocrinology, Novo Nordisk, P Biotech, NK Capital Investment, NK Capital, Starbucks, McDonalds, Bleecker Street Capital, Orso Partners, Justice Department, Federal Trade Commission, Safkhet, Global Education Locations: New York, Canada, U.S

Search resuls for: "THERAPEUTICS"

25 mentions found